kabutan

K Pharma,Inc.(4896) Summary

4896
TSE Growth
K Pharma,Inc.
748
JPY
-13
(-1.71%)
Apr 30, 12:52 pm JST
4.66
USD
Apr 29, 11:52 pm EDT
Result
PTS
outside of trading hours
750
Apr 30, 11:28 am JST
Summary Chart Historical News Financial Result
PER
PBR
6.87
Yield
ー%
Margin Trading Ratio
Stock Price
Apr 30, 2026
Opening Apr 30, 9:00 am
750 JPY 4.68 USD
Previous Close Apr 28
761 JPY 4.78 USD
High Apr 30, 11:30 am
753 JPY 4.70 USD
Low Apr 30, 9:08 am
741 JPY 4.62 USD
Volume
6,700
Trading Value
5.00M JPY 0.03M USD
VWAP
746.42 JPY 4.65 USD
Minimum Trading Value
74,800 JPY 466 USD
Market Cap
8.69B JPY 0.05B USD
Number of Trades
39
Liquidity & Number of Trades
As of Apr 30, 2026
Liquidity
Mid
1-Year Average
313
1-Year High Sep 29, 2025
4,614
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 24, 2026 0 289,100
Apr 17, 2026 0 290,300
Apr 10, 2026 0 296,900
Apr 3, 2026 0 297,900
Mar 27, 2026 0 278,400
Company Profile
K Pharma, Inc. engages in the research and development, manufacturing, and sales of pharmaceuticals and regenerative medicine products. The company originated from Keio University.
Sector
Pharmaceuticals
K Pharma, Inc. is a company specializing in the research and development, manufacturing, and sales of pharmaceuticals and regenerative medicine products. The company primarily focuses on the central nervous system disease area, developing both iPS cell-based drug discovery and regenerative medicine businesses. In iPS drug discovery, K Pharma is advancing the development of treatments for intractable diseases such as ALS and Alzheimer's disease. In regenerative medicine, the company is working on developing iPS cell-derived neural progenitor cell transplantation therapies for neurological disorders like spinal cord injury and cerebral infarction. Through collaborations with universities and research institutions, K Pharma commercializes basic research findings and has established a revenue model based on licensing agreements with pharmaceutical companies. The company aims for early clinical application, promoting the development of groundbreaking treatments in areas with high unmet medical needs.